ROCHESTER, Minn.–(BUSINESS WIRE)–INTENT Biologics, a clinical-stage biotechnology company developing PEP Biologic as the first-in-class exosome-based biologic therapiesROCHESTER, Minn.–(BUSINESS WIRE)–INTENT Biologics, a clinical-stage biotechnology company developing PEP Biologic as the first-in-class exosome-based biologic therapies

INTENT Biologics Receives FDA Agreement Granting a Full Waiver for its Pediatric Study Plan for PEP Biologic™ in Advanced Wound Care

ROCHESTER, Minn.–(BUSINESS WIRE)–INTENT Biologics, a clinical-stage biotechnology company developing PEP Biologic as the first-in-class exosome-based biologic therapies for serious conditions with significant unmet medical need, announced today that the U.S. Food and Drug Administration (FDA) has agreed to INTENT’s Initial Pediatric Study Plan (iPSP) for PEP Biologic™ under IND 019567, supporting the company’s request for a full pediatric waiver for its forthcoming Biologics License Application (BLA).

FDA’s agreement reflects alignment that pediatric studies are not required for PEP Biologic’s flagship indication, diabetic foot ulcers (DFU) which is initiating a pivotal trial in 2026. The agreed iPSP provides regulatory clarity and removes the requirement to conduct clinical studies in the pediatric population as part of the DFU development program, contingent upon biologic licensure.

“FDA alignment on our pediatric study plan is another important regulatory milestone achieved as we advance PEP Biologic toward late-stage clinical development and eventual BLA submission,” said Suneet Varma, Chief Executive Officer of INTENT Biologics. “This agreement allows us to remain fully focused on delivering a first-in-class biologic therapy for adult patients suffering from DFU, one of many different chronic, non-healing wounds with significant unmet medical need, while maintaining a clear and efficient regulatory pathway.”

The pediatric waiver agreement follows the FDA’s recent Fast Track designation for PEP Biologic in diabetic foot ulcers and further strengthens INTENT’s regulatory position as the company prepares for late-stage clinical development and registration-enabling studies. Together, these achieved regulatory milestones support an efficient development strategy aligned with FDA expectations for serious adult-onset conditions where pediatric studies are impossible or highly impractical.

PEP Biologic is a platelet-derived exosome biologic designed to deliver regenerative signaling messages that modulate immune responses and promote tissue repair, supporting resolution of inflammation and tissue regeneration. INTENT Biologics is advancing PEP Biologic into clinical development for diabetic foot ulcers, chronic radiation ulcers, and advanced wound care indications based on a proprietary exosome platform originating from RION.

About PEP Biologic™

PEP Biologic (Purified Exosome Product) is a first-in-class exosome therapeutic discovered through Mayo Clinic Van Cleve Cardiac Regenerative Medicine Program and developed on RION’s industry-leading platelet-derived exosome biomanufacturing platform. Packaged as a shelf-stable lyophilized powder, each dose contains regenerative exosomes that deliver polyvalent biologic signals to induce tissue regeneration and regulate immune responses for accelerated healing. With a novel mechanism of action that reduces hyper-inflammation, regulates immune response and repairs & regenerates tissue, PEP Biologic is being advanced by INTENT Biologics into pivotal clinical trials for a range of advanced wound care indications where current treatments fail to address the underlying biology.

About INTENT Biologics

INTENT Biologics is a clinical-stage biotechnology company dedicated to developing first-in-class exosome-based therapeutics in Advanced Wound Care. Spun out of RION, a global leader in regenerative exosome science, and built on more than two decades of research at the Mayo Clinic, INTENT is advancing PEP Biologic into late-stage clinical development for multiple indications in advanced tissue regeneration. Headquartered in Minnesota, the company is focused on “revolutionizing and replacing” standards of care in chronic wounds by harnessing regenerative exosomes to treat diseases with significant unmet need. More information can be found at www.intent.bio.

About RION

RION is a clinical-stage regenerative medicine company founded out of the Mayo Clinic after two decades of stem cell and exosome research and innovation. RION is the global leader in isolating and mass-producing platelet-derived regenerative exosomes into a proprietary therapeutic platform to produce Purified Exosome Product (PEP), a shelf-stable biologic designed to activate the body’s natural healing processes. RION is advancing a deep pipeline with clinical and preclinical programs in diabetic foot ulcers, knee osteoarthritis, musculoskeletal injury, dermatologic conditions, pulmonary disease, cardiovascular health, and women’s health. RION’s regenerative PEP technology will be integral to the therapeutic exosome revolution. More information can be found at www.riontx.com.

Contacts

Investor Relations
[email protected]

Market Opportunity
PEP Logo
PEP Price(PEP)
$0.000242
$0.000242$0.000242
-1.14%
USD
PEP (PEP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Talos Extends Series B to $150M With Strategic Institutional Investors

Talos Extends Series B to $150M With Strategic Institutional Investors

The post Talos Extends Series B to $150M With Strategic Institutional Investors appeared on BitcoinEthereumNews.com. Talos raises an additional $45 million in a
Share
BitcoinEthereumNews2026/01/31 07:49
Headwind Helps Best Wallet Token

Headwind Helps Best Wallet Token

The post Headwind Helps Best Wallet Token appeared on BitcoinEthereumNews.com. Google has announced the launch of a new open-source protocol called Agent Payments Protocol (AP2) in partnership with Coinbase, the Ethereum Foundation, and 60 other organizations. This allows AI agents to make payments on behalf of users using various methods such as real-time bank transfers, credit and debit cards, and, most importantly, stablecoins. Let’s explore in detail what this could mean for the broader cryptocurrency markets, and also highlight a presale crypto (Best Wallet Token) that could explode as a result of this development. Google’s Push for Stablecoins Agent Payments Protocol (AP2) uses digital contracts known as ‘Intent Mandates’ and ‘Verifiable Credentials’ to ensure that AI agents undertake only those payments authorized by the user. Mandates, by the way, are cryptographically signed, tamper-proof digital contracts that act as verifiable proof of a user’s instruction. For example, let’s say you instruct an AI agent to never spend more than $200 in a single transaction. This instruction is written into an Intent Mandate, which serves as a digital contract. Now, whenever the AI agent tries to make a payment, it must present this mandate as proof of authorization, which will then be verified via the AP2 protocol. Alongside this, Google has also launched the A2A x402 extension to accelerate support for the Web3 ecosystem. This production-ready solution enables agent-based crypto payments and will help reshape the growth of cryptocurrency integration within the AP2 protocol. Google’s inclusion of stablecoins in AP2 is a massive vote of confidence in dollar-pegged cryptocurrencies and a huge step toward making them a mainstream payment option. This widens stablecoin usage beyond trading and speculation, positioning them at the center of the consumption economy. The recent enactment of the GENIUS Act in the U.S. gives stablecoins more structure and legal support. Imagine paying for things like data crawls, per-task…
Share
BitcoinEthereumNews2025/09/18 01:27
Tether Achieves Record-Breaking $10 Billion Net Profit as Gold Strategy Redefines Stablecoin Reserves

Tether Achieves Record-Breaking $10 Billion Net Profit as Gold Strategy Redefines Stablecoin Reserves

Tether's extraordinary financial performance in 2025 has fundamentally altered the stablecoin landscape, generating over $10 billion in net profit while amassing
Share
Blockchainmagazine2026/01/31 08:04